Study of Disordered Mesoporous Silica Regarding Intrinsic Compound Affinity to the Carrier and Drug-Accessible Surface Area

Hollow mesoporous silica nanoparticles for drug formulation and delivery: Opportunities for cancer therapy

The advantages of large surface area, high volume ratio, good biocompatibility, and controllable surface functionalization make hollow mesoporous silica nanoparticles (HMSNs) an ideal drug carrier. HMSNs can achieve high efficiency, targeting, and controlled release by adjusting the microstructure and surface modification of its particles, which makes it broad application prospects in the field of medical therapy, especially in cancer therapy. Numerous studies have shown that preparation method, shape, particle size, hollow inner diameter, aperture and wall thickness of the HMSNs, the characteristics of the drugs, the interaction between the drugs and the carriers, and the external environment all closely affect the drug delivery, release, and efficacy. The external environment includes temperature, pH value, light intensity, magnetic field intensity, enzyme type and concentration, etc. This review summarizes the research progress of HMSNs as carrier materials in the past five years, analyzes the existing problems in the application process and presents the development prospects of HMSNs.

Process-Induced Crystal Surface Anisotropy and the Impact on the Powder Properties of Odanacatib

Crystalline active pharmaceutical ingredients with comparable size and surface area can demonstrate surface anisotropy induced during crystallization or downstream unit operations such as milling. To the extent that varying surface properties impacts bulk powder properties, the final drug product performance such as stability, dissolution rates, flowability, and dispersibility can be predicted by understanding surface properties such as surface chemistry, energetics, and wettability. Here, we investigate the surface properties of different batches of Odanacatib prepared through either jet milling or fast precipitation from various solvent systems, all of which meet the particle size specification established to ensure equivalent biopharmaceutical performance. This work highlights the use of orthogonal surface techniques such as Inverse Gas Chromatography (IGC), Brunauer-Emmett-Teller (BET) surface area, contact angle, and X-ray Photoelectron Spectroscopy (XPS) to demonstrate the effect of processing history on particle surface properties to explain differences in bulk powder properties.

High loading of lipophilic compounds in mesoporous silica for improved solubility and dissolution performance

Loading poorly soluble active pharmaceutical ingredients (API) into mesoporous silica can enable API stabilization in non-crystalline form, which leads to improved dissolution. This is particularly beneficial for highly lipophilic APIs (log D7.4 > 8) as these drugs often exhibit limited solubility in dispersion forming carrier polymers, resulting in low drug load and reduced solid state stability. To overcome this challenge, we loaded the highly lipophilic natural products coenzyme Q10 (CoQ10) and astaxanthin (ASX), as well as the synthetic APIs probucol (PB) and lumefantrine (LU) into the mesoporous silica carriers Syloid® XDP 3050 and Silsol® 6035. All formulations were physically stable in their non-crystalline form and drug loads of up to 50 % were achieved. At increasing drug loads, a marked increase in equilibrium solubility of the active ingredients in biorelevant medium was detected, leading to improved performance during biorelevant biphasic dissolution studies (BiPHa + ). Particularly the natural products CoQ10 and ASX showed substantial benefits from being loaded into mesoporous carrier particles and clearly outperformed currently available commercial formulations. Performance differences between the model compounds could be explained by in silico calculations of the mixing enthalpy for drug and silica in combination with an experimental chromatographic method to estimate molecular interactions.